The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2023 | Elucidating the optimal total neoadjuvant therapy in rectal cancer
Lucjan Wyrwicz, MD, PhD, Maria Sklodowska-Curie National Cancer Research Institute, Warsaw, Poland, comments on the latest developments in total neoadjuvant therapy for patients with rectal cancer. Trials including the Polish II study (NCT00833131) have demonstrated the benefits of total neoadjuvant therapy in terms of limiting metastasis, but improvements in local disease control have yet to be seen. Further real-world studies are additionally needed to assess whether short course or long course radiotherapy is superior, and international cohorts will be pivotal to make this possible. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
